All In Biotech

Drug Trial Radar · NCT04159415

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

A Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Jan 7, 2020

Primary completion

Jan 5, 2022

Study completion Sep 24, 2024

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride levels in the subset of patients with elevated baseline fasting triglycerides (TG ≥250 mg/dL). The secondary objectives are to estimate the effects of REGN4461 on a composite endpoint of changes in either HbA1c or fasting TG for all patients, estimate the effects of 3 dose levels of REGN4461 on glycemic parameters and fasting TG, to estimate the effects of REGN4461 on insulin sensitivity, to evaluate the safety and tolerability of REGN4461 and to evaluate the pharmacokinetics (PK) and immunogenicity of REGN4461.

Conditions

  • Generalized Lipodystrophy

Interventions

  • PlaceboDrug

    Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).

  • Low-Dose REGN4461Drug

    IV infusion loading dose or SC injection QW.

  • High-dose REGN4461Drug

    IV infusion loading dose or SC injection QW.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8Time frame: Baseline, Week 8
  2. Absolute Change From Baseline in Fasting Glucose at Week 8Time frame: Baseline, Week 8
  3. Absolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8Time frame: Baseline, Week 8
  4. Percent Change From Baseline in Fasting Triglycerides (TG) at Week 8Time frame: Baseline, Week 8

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Regeneron Research Site

    Bethesda, Maryland

  • Regeneron Research Site

    Ann Arbor, Michigan

  • Regeneron Research Site

    Dallas, Texas

  • Regeneron Research Site

    Piura, Peru

  • Regeneron Research Site

    Moscow, Russia

  • Regeneron Research Site

    Ankara, Turkey (Türkiye)

  • Regeneron Research Site

    Diyarbakır, Turkey (Türkiye)

  • Regeneron Research Site

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.